MLTX insider buying and SEC filings, explained
MoonLake Immunotherapeutics · CIK 1821586
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$71.7M
Planned sales (10b5-1)
$11.3M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jul 27, 2026 | Planned (10b5-1) | Kristian Reich (Chief Scientific Officer) sold 1,100 shares indirectly at $20.00 ($22K), marked as a 10b5-1 plan trade. Indirect holdings down <1% to 2,711,198 shares. | SEC filing Filed Jul 29, 2026 |
| Jul 21–22, 2026 | Planned (10b5-1) | Kristian Reich (Chief Scientific Officer) sold 52,448 shares indirectly between Jul 21 and Jul 22 at about $20.02 ($1.0M), marked as a 10b5-1 plan trade. Indirect holdings down 2% to 2,712,298 shares. | SEC filing Filed Jul 23, 2026 |
| Jul 20, 2026 | Planned (10b5-1) | Kristian Reich (Chief Scientific Officer) sold 43,700 shares indirectly at about $20.09 ($878K), marked as a 10b5-1 plan trade. Indirect holdings down 2% to 2,764,746 shares. | SEC filing Filed Jul 21, 2026 |
| Jul 15, 2026 | Planned (10b5-1) | Kristian Reich (Chief Scientific Officer) sold 16,105 shares indirectly at about $20.01 ($322K), marked as a 10b5-1 plan trade. Indirect holdings down 1% to 2,808,446 shares. | SEC filing Filed Jul 20, 2026 |
| Jul 9–10, 2026 | Planned (10b5-1) | da Silva Jorge Santos (CEO and Director) sold 102,225 shares between Jul 9 and Jul 10 at about $20.02 ($2.0M), marked as a 10b5-1 plan trade. Holdings down 4% to 2,774,893 shares. | SEC filing Filed Jul 13, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | da Silva Jorge Santos (CEO and Director) sold 47,775 shares at about $20.03 ($957K), marked as a 10b5-1 plan trade. Holdings down 2% to 2,877,118 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Matthias Bodenstedt (CFO) sold 39,120 shares at about $22.04 ($862K), marked as a 10b5-1 plan trade. Holdings down 3% to 1,115,435 shares. | SEC filing Filed Jun 23, 2026 |
| Jun 17–18, 2026 | Planned (10b5-1) | Matthias Bodenstedt (CFO) sold 17,876 shares between Jun 17 and Jun 18 at about $19.67 ($352K), marked as a 10b5-1 plan trade. Holdings down 2% to 1,154,555 shares. | SEC filing Filed Jun 18, 2026 |
| Jun 15–17, 2026 | Planned (10b5-1) | Kristian Reich (Chief Scientific Officer) sold 150,000 shares indirectly between Jun 15 and Jun 17 at about $19.01 ($2.9M), marked as a 10b5-1 plan trade. Indirect holdings down 5% to 2,824,551 shares. | SEC filing Filed Jun 17, 2026 |
| May 11, 2026 | Planned (10b5-1) | Matthias Bodenstedt (CFO) sold 13,653 shares at about $20.02 ($273K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,172,431 shares. | SEC filing Filed May 13, 2026 |
| Apr 14, 2026 | Planned (10b5-1) | Matthias Bodenstedt (CFO) sold 2,426 shares at about $19.56 ($47K), marked as a 10b5-1 plan trade. Holdings down <1% to 1,186,084 shares. | SEC filing Filed Apr 16, 2026 |
| Apr 10–13, 2026 | Sale | da Silva Jorge Santos (CEO and Director) sold 150,000 shares between Apr 10 and Apr 13 at about $18.35 ($2.8M). Holdings down 5% to 2,924,893 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 14, 2026 |
| Apr 9–10, 2026 | Planned (10b5-1) | Matthias Bodenstedt (CFO) sold 87,795 shares between Apr 9 and Apr 10 at about $18.95 ($1.7M), marked as a 10b5-1 plan trade. Holdings down 7% to 1,188,510 shares. | SEC filing Filed Apr 10, 2026 |
| Mar 31, 2026 | Sale | Mark N. Lampert (Director and 10% owner) sold 3,750,000 shares at $16.79 ($63.0M). Holdings down 78% to 1,039,238 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 9 other reporting owners. | SEC filing Filed Apr 2, 2026 |
| Dec 8–9, 2025 | Sale | da Silva Jorge Santos (CEO and Director) sold 200,000 shares between Dec 8, 2025 and Dec 9, 2025 at about $14.87 ($3.0M). Holdings down 6% to 2,878,577 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 10, 2025 |
| Dec 8–9, 2025 | Sale | Kristian Reich (Chief Scientific Officer) sold 202,908 shares between Dec 8, 2025 and Dec 9, 2025 at about $14.85 ($3.0M). Holdings down 100% to 0 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 10, 2025 |
11 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow MLTX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.